IL133070A0 - Composition and method to prevent graft rejection and other counter-adaptive t lymphocyte mediated immune responses - Google Patents

Composition and method to prevent graft rejection and other counter-adaptive t lymphocyte mediated immune responses

Info

Publication number
IL133070A0
IL133070A0 IL13307098A IL13307098A IL133070A0 IL 133070 A0 IL133070 A0 IL 133070A0 IL 13307098 A IL13307098 A IL 13307098A IL 13307098 A IL13307098 A IL 13307098A IL 133070 A0 IL133070 A0 IL 133070A0
Authority
IL
Israel
Prior art keywords
adaptive
counter
composition
immune responses
graft rejection
Prior art date
Application number
IL13307098A
Other languages
English (en)
Original Assignee
Us Navy
Wisconsin Alumni Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Navy, Wisconsin Alumni Res Found filed Critical Us Navy
Publication of IL133070A0 publication Critical patent/IL133070A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL13307098A 1997-06-11 1998-06-10 Composition and method to prevent graft rejection and other counter-adaptive t lymphocyte mediated immune responses IL133070A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4938997P 1997-06-11 1997-06-11
PCT/US1998/011910 WO1998056417A1 (fr) 1997-06-11 1998-06-10 Composition et procede pour prevenir des rejets de greffe ou d'autres reponses immunitaires non adaptives des lymphocytes t

Publications (1)

Publication Number Publication Date
IL133070A0 true IL133070A0 (en) 2001-03-19

Family

ID=21959563

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13307098A IL133070A0 (en) 1997-06-11 1998-06-10 Composition and method to prevent graft rejection and other counter-adaptive t lymphocyte mediated immune responses

Country Status (6)

Country Link
EP (1) EP1009432A4 (fr)
JP (1) JP2002504120A (fr)
AU (1) AU748533B2 (fr)
CA (1) CA2291338A1 (fr)
IL (1) IL133070A0 (fr)
WO (1) WO1998056417A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887471B1 (en) 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
JP2002533118A (ja) * 1998-12-29 2002-10-08 ユニバーシティ オブ バーモント アンド ステイト アグリカルチャー カレッジ Ｔ細胞レセプター使用を改変するためのｃｄ４０係合の使用
CA2358435A1 (fr) * 1999-01-08 2000-07-13 Stuart J. Knechtle Procede permettant de prolonger la duree de survie d'une greffe a l'aide d'immunotoxines et par blocage de costimulation des cd154 et cd28
JP2003520828A (ja) * 2000-01-27 2003-07-08 ジェネティクス インスティテュート，エルエルシー Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用
US6797263B2 (en) 2000-05-12 2004-09-28 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for achieving immune suppression
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
CA2411962A1 (fr) * 2000-06-09 2001-12-20 Bristol-Myers Squibb Company Procedes de regulation de reponse immunitaire a mediation cellulaire au moyen du blocage des signaux lymphocytaires et du blocage de l'adhesion induite par l'antigene lfa-1
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
TR201807700T4 (tr) 2000-07-03 2018-06-21 Squibb Bristol Myers Co Çözünür CTLA4 mutant moleküllerinin kullanımları.
JP4463475B2 (ja) * 2001-01-31 2010-05-19 バイオジェン アイデック インコーポレイテッド 腫瘍疾患の治療における免疫調節性抗体の使用
EP1241249A1 (fr) * 2001-03-12 2002-09-18 Gerold Schuler Lymphocytes T CD4+CD25+ régulateurs provenant du sang humain
US20050101012A1 (en) 2001-03-12 2005-05-12 Gerold Schuler CD4+CD25+ regulatory T cells from human blood
DE60225914T2 (de) 2001-05-23 2009-07-23 Bristol-Myers Squibb Co. Verfahren zum schützen eines allogenen inseltransplantats mit löslichen ctla4-mutationsmolekülen
US8222033B2 (en) 2002-08-12 2012-07-17 Argos Therapeutics, Inc. CD4+CD25− T cells and Tr1-like regulatory T cells
GB0815788D0 (en) * 2008-08-29 2008-10-08 Isis Innovation Therapeutic antibodies
WO2019245039A1 (fr) 2018-06-22 2019-12-26 株式会社Ｊｕｎｔｅｎ Ｂｉｏ Composition pour déclencher une tolérance immunologique infectieuse
EP3811952A4 (fr) 2018-06-22 2022-06-01 JUNTEN BIO Co., Ltd. Anticorps capable d'induire une tolérance immunitaire produit à l'aide d'un mélange cellulaire à l'état complexé, et agent thérapeutique cellulaire ou lymphocytaire induit et méthode de thérapie cellulaire utilisant chacun un lymphocyte induit
US20210269529A1 (en) 2018-06-22 2021-09-02 Junten Bio Co., Ltd. Antibody inducing immune tolerance, induced lymphocyte, and cell therapy agent therapeutic method using induced lymphocyte
WO2023153388A1 (fr) * 2022-02-08 2023-08-17 学校法人順天堂 Méthode d'allogreffe et méthode de prévention de rejet

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2701895A (en) * 1994-06-07 1996-01-05 Regents Of The University Of Minnesota Methods for inhibiting antigen specific t cell responses
EP0892643B2 (fr) * 1996-03-20 2009-09-02 Bristol-Myers Squibb Company Procedes d'inhibition d'une reponse immune par blocage des voies de gp39/cd40 et ctla4/cd28/b7 et compositions utilisees avec ceux-ci

Also Published As

Publication number Publication date
EP1009432A1 (fr) 2000-06-21
AU748533B2 (en) 2002-06-06
AU7956798A (en) 1998-12-30
WO1998056417A1 (fr) 1998-12-17
EP1009432A4 (fr) 2004-07-07
JP2002504120A (ja) 2002-02-05
CA2291338A1 (fr) 1998-12-17

Similar Documents

Publication Publication Date Title
IL133070A0 (en) Composition and method to prevent graft rejection and other counter-adaptive t lymphocyte mediated immune responses
IL118589A0 (en) Compositions and method for improving autologous fat grafting
IL115551A0 (en) Intraluminal graft and method for insertion thereof
GB2288257B (en) Improved nutritional micromcomputer and method
AR244539A1 (es) Un metodo para preparacion de una composicion de injerto de tejido a partir de un segmento de intestino delgado.
HUP0000302A3 (en) Ob fusion protein compositions and methods
ZA964733B (en) Ob protein compositions and methods
EP0833615A4 (fr) Compose nutritionnel et/ou dietetique et son procede d'utilisation
ZA958028B (en) Compositions and methods for treatig mast-cell mediated conditions
AU6237596A (en) Angiosurgical device and vascular graft and vascular annulusfor vessel-vascular graft binding
PL321935A1 (en) Electroplating compositions and methods
GB9604829D0 (en) Method and composition
EP0555413A4 (en) Methods and compositions for suppressing allograft rejection in mammals
ZA989398B (en) Method and composition (l)
PL327853A1 (en) Materials and methods related to exodus chemokin
GB2318356B (en) Composition and method
GB9408342D0 (en) Method and composition
GB9414888D0 (en) Method and composition
GB9419087D0 (en) Method and composition
AU6648498A (en) Methods and compositions using interleukin-13 for enhancing immune responses
GB9026896D0 (en) Method and composition
GB9601656D0 (en) Novel composition and method
GB9025513D0 (en) Incendiary method and composition
ZA919566B (en) Jumper switch means and method
GB9503315D0 (en) Composition and method